Literature DB >> 24163512

Fluoro-deoxy-glucose positron emission tomography/computed tomography in lymphoma: A pictorial essay.

Kuruva Manohar1, Bhagwant Rai Mittal, Anish Bhattacharya, Pankaj Malhotra, Subhash Varma.   

Abstract

F-18 fluoro-deoxy-glucose (FDG) positron emission tomography/computed tomography (PET/CT) has emerged as a powerful imaging modality in the field of oncology. F-18 FDG PET/CT is now an established tool in the management of lymphoma. This has been shown to be useful in staging, detection of bone marrow involvement (BMI), early response assessment and end of therapy response assessment in lymphoma. Interpretation of F-18 FDG PET/CT in lymphoma is carried out by various qualitative response assessment criteria. London criteria are used for interpretation of interim PET/CT and International Harmonization Project (IHP) criteria are used to interpret PET/CT done after the end of chemotherapy. Quantitative analysis is also found to be useful in assessment of response early after two cycles of chemotherapy in patients with diffuse large B cell lymphoma (DLBCL). This pictorial essay provides few images describing the FDG avidity of lymphoma, patterns of bone marrow uptake and their relevance in predicting BMI, role of staging PET/CT, quantitative analysis in response assessment, example images of response according to London criteria and IHP criteria. Few pitfalls in imaging of lymphoma with PET/CT are also discussed in the images legend.

Entities:  

Keywords:  F-18 fluoro-deoxy-glucose; lymphoma; positron emission tomography/computed tomography

Year:  2013        PMID: 24163512      PMCID: PMC3800317          DOI: 10.4103/0972-3919.118256

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


  14 in total

1.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

Authors:  Sally F Barrington; Wendi Qian; Edward J Somer; Antonella Franceschetto; Bruno Bagni; Eva Brun; Helén Almquist; Annika Loft; Liselotte Højgaard; Massimo Federico; Andrea Gallamini; Paul Smith; Peter Johnson; John Radford; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

2.  Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

Authors:  Chieh Lin; Emmanuel Itti; Corinne Haioun; Yolande Petegnief; Alain Luciani; Jehan Dupuis; Gaetano Paone; Jean-Noël Talbot; Alain Rahmouni; Michel Meignan
Journal:  J Nucl Med       Date:  2007-09-14       Impact factor: 10.057

3.  (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.

Authors:  Gerard Moulin-Romsee; Elif Hindié; Xavier Cuenca; Pauline Brice; Didier Decaudin; Myriam Bénamor; Josette Brière; Marcela Anitei; Jean-Emmanuel Filmont; David Sibon; Eric de Kerviler; Jean-Luc Moretti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-04       Impact factor: 9.236

4.  18F-FDG-PET/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences.

Authors:  A M García Vicente; M Bellón Guardia; A Soriano Castrejón; C Calle Primo; J M Cordero García; A Palomar Muñoz; J P Pilkington Woll; M P Talavera Rubio; B Hernández Ruiz
Journal:  Rev Esp Med Nucl Imagen Mol       Date:  2011-07-13       Impact factor: 1.359

5.  Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging?

Authors:  Bhagwant Rai Mittal; Kuruva Manohar; Pankaj Malhotra; Reena Das; Raghava Kashyap; Anish Bhattacharya; Neelam Varma; Subhash Varma
Journal:  Leuk Lymphoma       Date:  2011-07-12

6.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

7.  Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center.

Authors:  Tarec El-Galaly; Vineet Prakash; Ilse Christiansen; Jakob Madsen; Preben Johansen; Martin Boegsted; Hans-Erik Johnsen; Anne Bukh
Journal:  Leuk Lymphoma       Date:  2011-02-14

8.  Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.

Authors:  Pierre-Yves Le Roux; Thomas Gastinne; Steven Le Gouill; Emmanuel Nowak; Caroline Bodet-Milin; Solène Querellou; Beatrice Mahe; Viviane Dubruille; Nicolas Blin; Pierre Yves Salaun; Françoise Bodere-Kraeber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-10       Impact factor: 9.236

9.  Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma.

Authors:  Ludovic Le Dortz; Sophie De Guibert; Sahar Bayat; Anne Devillers; Roch Houot; Yan Rolland; Marc Cuggia; Florence Le Jeune; Haïfa Bahri; Marie-Luce Barge; Thierry Lamy; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-18       Impact factor: 9.236

10.  (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients.

Authors:  Michal Weiler-Sagie; Olga Bushelev; Ron Epelbaum; Eldad J Dann; Nissim Haim; Irit Avivi; Ayelet Ben-Barak; Yehudit Ben-Arie; Rachel Bar-Shalom; Ora Israel
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

View more
  1 in total

1.  Feasibility of a multimodal (18)F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma.

Authors:  Stephen P Povoski; Nathan C Hall; Douglas A Murrey; Chadwick L Wright; Edward W Martin
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.